BIOCON

Biologics tightens grip on Adalimumab franchise 💉🌍

Biologics has secured full and exclusive global rights for HULIO (biosimilar Adalimumab) from Fujifilm Kyowa Kirin Biologics. The revised agreement gives Biocon end-to-end control over manufacturing, development, and commercialization, strengthening ownership across the value chain. This move upgrades Biocon’s position from a pure commercial partner to a fully integrated biosimilars player, improving supply control and long-term strategic flexibility. Adalimumab remains a key pillar in Biocon Biologics’ immunology portfolio, reinforcing its focus on scaling global access to complex biologics. More control, stronger portfolio, and deeper biosimilars moat.